Publicaciones en las que colabora con Juan Antonio Pineda Vergara (15)

2024

  1. Long or complicated mpox in patients with uncontrolled HIV infection

    Journal of Medical Virology, Vol. 96, Núm. 3

2019

  1. Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

    Pharmacogenomics Journal, Vol. 17, Núm. 4, pp. 360-365

  2. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study

    PLoS ONE, Vol. 11, Núm. 5

  2. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort

    PLoS ONE, Vol. 11, Núm. 2

2013

  1. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  2. Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

    PLoS ONE, Vol. 8, Núm. 7

2012

  1. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205

  2. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients

    AIDS, Vol. 26, Núm. 8, pp. 1009-1015

2011

  1. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 11, pp. 2605-2614

  2. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 6, pp. 1351-1353

2010

  1. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 10, pp. 2204-2211

  2. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: Role of didanosine

    Antiviral Therapy, Vol. 15, Núm. 5, pp. 753-763

2009

  1. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients

    Gut, Vol. 58, Núm. 12, pp. 1654-1660